Author:
Penault-Llorca Frederique,Radosevic-Robin Nina
Publisher
Springer International Publishing
Reference86 articles.
1. Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis-Filho JS, Ellis IO, Rakha EA (2012) Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res 14(1):R3. doi: 10.1186/bcr3084
2. Alvarado MD, Prasad C, Rothney M, Cherbavaz DB, Sing AP, Baehner FL, Svedman C, Markopoulos CJ (2015) A prospective comparison of the 21-gene recurrence score and the PAM50-based prosigna in estrogen receptor-positive early-stage breast cancer. Adv Ther. doi: 10.1007/s12325-015-0269-2
3. Andre F, Arnedos M, Goubar A, Ghouadni A, Delaloge S (2015) Ki67—no evidence for its use in node-positive breast cancer. Nat Rev Clin Oncol 12(5):296–301. doi: 10.1038/nrclinonc.2015.46
4. Beresford MJ, Wilson GD, Makris A (2006) Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 8(6):216. doi: 10.1186/bcr1618
5. Canepa M, Gambini C, Sementa AR, Borgiani L, Rovida S (1990) Nucleolar organizer regions and Ki-67 immunostaining in ductal breast cancer: a comparative study. Pathologica 82(1078):125–132